Review of 27 pivotal phase III haemophilia trials (extended half-life factors, nonfactor and gene therapies) found 67% gave no bleed event definition, only 63% used annualised bleed rate as primary outcome, and most observed patients for under 52 weeks.
Guidelinen = 27 trials
Croteau et al. Assessment of documentation and reporting methods for annual bleeding rate in hemophilia clinical trials: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX, and Rare Coagulation Disorders